ArticleJournal of veterinary internal medicine2026
ClotPro viscoelastic testing in coagulation disorders in dogs: a retrospective analysis.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViscoelastic testing provides whole-blood assessment of coagulation, but clinical data on the performance of the ClotPro in dogs with naturally occurring diseases are limited. HYPOTHESIS/
objectivesTo evaluate pathway coherence of ClotPro variables with routine coagulation tests and to explore disease-associated viscoelastic phenotypes, fibrinolysis, and hypercoagulability. ANIMALS: Eighty-four client-owned dogs admitted to a university hospital.
methodsRetrospective cohort study. ClotPro variables (clotting time, amplitude at 10 min, maximum clot firmness, maximum lysis across extrinsic pathway test [EX], intrinsic pathway test [IN], fibrinogen test channel, aprotinin test [AP] channels) were compared with prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count (PLT), and D-dimer using Spearman correlation with Benjamini-Hochberg adjustment. Group differences were assessed with Kruskal-Wallis and Dunn's post hoc. Hyperfibrinolysis (HF) was defined using paired EX-AP. A hypercoagulability index (HCI) and platelet/fibrin-adjusted residual firmness were derived.
resultsPT correlated with clotting time in EX channel (ρ = 0.48, q = 0.002) and aPTT with clotting time in IN channel (ρ = 0.42, q = 0.007). PLT correlated with maximum clot firmness in EX channel (EX_MCF) (ρ = 0.50, q = 0.001). maximum clot firmness in FIB channel correlated with EX_MCF (ρ = 0.58, q < 0.001) and maximum clot firmness in IN channel (ρ = 0.47, q = 0.003). maximum lysis in EX channel (EX_ML) correlated inversely with EX_MCF (ρ = -0.35, q = 0.028). D-dimer correlated with EX_ML (ρ = 0.30, q = 0.049). Group-level distributions overlapped substantially. HF was infrequent among cases (33% in dogs with hepatopathy and 21% in dogs with hemorrhagic diarrhea). The HCI differed across diseases (P = .0002), whereas platelet/fibrin-adjusted residual firmness did not. CONCLUSIONS AND CLINICAL IMPORTANCE: ClotPro variables demonstrated pathway-specific coherence with routine coagulation testing and consistent fibrinolysis patterns. Disease states did not define discrete viscoelastic phenotypes, supporting case-level interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.